Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants.
Carreño
M R
MR
Department of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Kato
T
T
Weppler
D
D
Mathew
J M
JM
Fuller
L
L
Gomez
C
C
Salman
F
F
Garcia-Morales
R
R
Ciancio
G
G
Burke
G W
GW
Esquenazi
V
V
Miller
J
J
Tzakis
A G
AG
D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000627:therapeutic use*; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use*; D007421:Intestine, Small / Q000637:transplantation*; D008297:Male; D016377:Organ Transplantation; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab